$3.18
0.32% yesterday
Nasdaq, Jul 03, 10:00 pm CET
ISIN
US88032L2097
Symbol
TENX

Tenax Therapeutics, Inc. Share price

$3.18
-0.33 9.40% 1M
-12.82 80.13% 6M
-18.79 85.52% YTD
-21.22 86.97% 1Y
-3,148.82 99.90% 3Y
-2,164.82 99.85% 5Y
-125,116.82 100.00% 10Y
Nasdaq, Closing price Wed, Jul 03 2024
+0.01 0.32%
ISIN
US88032L2097
Symbol
TENX
Sector

Key metrics

Market capitalization $6.23m
Enterprise Value $-5.91m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.63
P/B ratio (TTM) P/B ratio 0.50
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-10.60m
Free cash flow (TTM) Free cash flow $-9.34m
Cash position $12.55m
EPS (TTM) EPS $-24.54
P/E ratio expected negative
Short interest 0.51%
Show more

Is Tenax Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.

Tenax Therapeutics, Inc. Share analysis

Unlock Scores for Free

Analyst opinions

1 Analyst has issued a forecast Tenax Therapeutics, Inc.:

1x Buy
100%

Analyst opinions

1 Analyst has issued a forecast Tenax Therapeutics, Inc.:

Buy
100%

Financial data from Tenax Therapeutics, Inc.

Mar '24
+/-
%
Net profit -3.80 -3.80
170% 170%
-
Depreciation and amortization - -
-
-
Share compensation 0.12 0.12
71% 71%
-
Operating cash flow -5.17 -5.17
201% 201%
-
Investments - -
-
-
Dividend paid - -
-
-
Free cash flow -5.17 -5.17
-
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the Tenax Therapeutics, Inc. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Tenax Therapeutics, Inc. Share News

Neutral
GlobeNewsWire
about 2 months ago
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for  Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent Recently Hosted KOL Event, “LEVEL Setting,” Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFp...
Neutral
GlobeNewsWire
2 months ago
CHAPEL HILL, N.C., April 30, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a pate...
Neutral
GlobeNewsWire
3 months ago
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role for levosimendan in treating this prevalent, fatal disease
More Tenax Therapeutics, Inc. News

Company profile

Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

Head office United States
CEO Christopher Giordano
Employees 5
Founded 1967
Website www.tenaxthera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today